CRVS— Corvus Pharmaceuticals, Inc.

$11.60-0.77%

NasdaqMaterialsPharmaceutical Preparations

1 insider bought $83K worth of CRVS in the last 30 days — 24.0x above historical baseline

Velocity Score — Last 14 Days

Velocity Score

23.98x

Current Rate (90d)

77.02 sh/day

Baseline Rate

—

Unique Insiders (90d)

Price Chart

Loading…

Insider Transactions

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-05-18	2026-05-20	MILLER RICHARD A MD	Director & President and CEO	Purchase	6,932	$12.04	$83K	1.20M	View ↗
2025-06-27	2025-07-01	ORBIMED ADVISORS LLC	Director	Sale	1.18M	$4.16	$4.89M	7.17M	View ↗

No recent congressional transactions.

Revenue

No data

Operating Income

No data

Net Income

No data

Free Cash Flow

-$33.0M

-29.5% YoY

No annual data found.

Adams Street Partners Exits Its 223,000-Share Paymentus (PAY) Position for $5.9 Million

Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference

Corvus Pharmaceuticals: The Market Is Pricing Atopic Dermatitis Success Too Early

Corvus Pharmaceuticals, Inc. (CRVS) Shareholder/Analyst Call - Slideshow